Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Esophageal Neoplasms 25Rectal Neoplasms 23Glioblastoma 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Breast Neoplasms 17Pancreatic Neoplasms 16Lung Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 14Neoplasms 12Oropharyngeal Neoplasms 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Adenocarcinoma Of Esophagus 8Uterine Cervical Neoplasms 7Glioma 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Gliosarcoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Melanoma 5Laryngeal Neoplasms 5Colorectal Neoplasms 5Xerostomia 4Sarcoma 4Mouth Neoplasms 4

Interventions

Rituximab 57Cyclophosphamide 42fludarabine phosphate 29Peripheral Blood Stem Cell Transplantation 29Mycophenolic Acid 22Dexamethasone 21Tacrolimus 20Whole-Body Irradiation 18Bortezomib 18Cyclosporine 15Busulfan 13ibrutinib 12Methotrexate 12Melphalan 12Radiotherapy 11Etoposide 11Antilymphocyte Serum 10zanubrutinib 9Calcium Dobesilate 9venetoclax 7Sirolimus 7idelalisib 6Prednisone 6Lenalidomide 6Filgrastim 6Doxorubicin 6Cyclosporins 6Bendamustine Hydrochloride 6Alemtuzumab 6sargramostim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Waldenstrom Macroglobulinemia × Radiation × Clear all
NCT00088881 2017-05-25

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
62 enrolled 8 charts
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡